HAA-09
HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1422051-33-9
- 分子式: C17H18F2N6O2
- 分子量:376.36
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
IC50: 0.06±0.004 μM (polymerase); EC50: 0.03 μM (influenza A virus)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
>100 μM
Compound: HAA-09
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by CCK-8 method
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by CCK-8 method
|
[PMID: 36773549] |
HAA-09 (0-25 mg/kg; Orally, BID) exhibits anti-influenza virus efficacy in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/C mice[1]
-
Dosage:40 mg/kg
-
Administration:Orally, QD (once daily) for consecutive 3 days
-
Result:Demonstrated a favorable safety profile when orally administrated in healthy mice.
-
Animal Model:Female BALB/c mice (6–8 weeks)[1]
-
Dosage:12.5, 25 mg/kg
-
Administration:Orally, BID (twice daily) starting 48 h post infection for 9 days
-
Result:Demonstrated in vivo therapeutic efficacy (85.7% survival observed at the day 15 post infection).
化学情報
-
CAS 番号 1422051-33-9
-
分子量 376.36
-
分子式 C17H18F2N6O2
-
SMILES
CC(C)(N(NC1=C(C=NC(C2=CNC3=C2C=C(C=N3)F)=N1)F)CC(O)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)